Orchestra BioMed’s AVIM Therapy: A Revolutionary Approach
Hypertensive heart disease is a considerable health concern, affecting millions and calling for innovative treatment solutions. At the recent Congenital, Structural, and Valvular Heart Disease Interventions Meeting, Orchestra BioMed unveiled significant insights into its Atrioventricular Interval Modulation (AVIM) therapy. This breakthrough therapy aims specifically at managing blood pressure in older patients who are at a heightened risk of heart complications.
The Challenge of Hypertensive Heart Disease
This condition impacts over 7.7 million patients, often linked with long-standing hypertension and an increased risk of cardiovascular events. Current therapeutic options for these individuals are limited, underscoring the importance of advancing innovative treatments like AVIM therapy. This novel approach could potentially be the solution to a pressing health issue.
AVIM Therapy Explained
AVIM therapy is designed to provide effective blood pressure management specifically tailored for patients with hypertensive heart disease. It works by modifying atrioventricular intervals, thereby reducing cardiac preload and enhancing the function of the autonomic nervous system to lower blood pressure. These adaptations aim to improve cardiovascular health outcomes significantly.
The Presentation at CSI 2025
During the conference, Dr. Daniel Burkhoff, a leading expert in heart failure, presented key findings about the therapy. His insights focused on how AVIM can fill the existing treatment gaps in managing patients prone to heart failure—a consequence often stemming from untreated hypertension.
Importance of Clinical Evidence
The presentation outlined not only the clinical burden of hypertensive heart disease but also detailed the growing body of evidence supporting AVIM therapy. Results from pilot studies demonstrated that patients using AVIM experienced significant reductions in both ambulatory and office systolic blood pressure levels. The change marks a critical advancement in addressing hypertension and its resultant complications effectively.
A Look at the BACKBEAT Study
Orchestra BioMed is actively conducting the BACKBEAT global pivotal study aimed at evaluating the safety and efficacy of AVIM therapy in lowering blood pressure among patients indicated for dual-chamber pacemakers. This study, conducted in collaboration with Medtronic, aims to validate the promising results seen in earlier trials and set new standards in patient care.
The Future of Hypertension Care
As stated by Dr. Avi Fischer, the Senior Vice President of Medical Affairs and Innovation at Orchestra BioMed, AVIM therapy offers a programmable and seamlessly integrated solution within existing electrophysiology practices. It represents a significant shift in how hypertensive heart disease is managed.
With the recent Breakthrough Device Designation status granted by the FDA, there is renewed hope for patients suffering from uncontrolled hypertension. This recognition further emphasizes the potential of AVIM therapy to transform healthcare practices and improve outcomes for individuals at high risk.
About Orchestra BioMed
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a pioneering biomedical firm focused on delivering high-impact technologies. Its collaborative approach with major medical device manufacturers aims to accelerate the commercialization of innovative treatments, particularly for hypertension with AVIM therapy. With additional projects underway, including the Virtue SAB for artery disease, the company is positioned at the forefront of enhancing patient outcomes in the cardiovascular domain.
Frequently Asked Questions
What is AVIM therapy?
AVIM therapy is a new investigational treatment designed to significantly lower blood pressure in patients with hypertensive heart disease.
Who presented the findings on AVIM therapy?
The findings were presented by Dr. Daniel Burkhoff, a recognized expert in heart failure management.
Why is there a need for AVIM therapy?
The therapy addresses the critical gaps in treatment options for patients with uncontrolled hypertension, especially among older populations at high risk for heart failure.
What studies support AVIM therapy's efficacy?
Pilot studies, including the MODERATO II study, show significant reductions in blood pressure among patients treated with AVIM therapy.
What role does Medtronic play in AVIM therapy's development?
Medtronic collaborates with Orchestra BioMed for the development and commercialization of AVIM therapy, leveraging their expertise in cardiac pacing therapy.
